Comparative Pharmacology
Head-to-head clinical analysis: DHIVY versus NORINYL 1 50 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DHIVY versus NORINYL 1 50 21 DAY.
DHIVY vs NORINYL 1+50 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dihydropyridine calcium channel blocker that selectively inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced peripheral vascular resistance.
Norinyl 1+50 21-Day contains norethindrone (a progestin) and mestranol (an estrogen). Mestranol is converted to ethinyl estradiol, which provides negative feedback on gonadotropin release, inhibiting ovulation. Norethindrone suppresses gonadotropins and alters cervical mucus and endometrial lining to prevent implantation.
DHIVY is not a recognized drug. No dosing information available.
One tablet (1 mg norethindrone + 0.05 mg mestranol) orally once daily for 21 days, followed by 7 placebo tablets. Start on day 1 of menstrual cycle or first Sunday after onset.
None Documented
None Documented
Terminal elimination half-life is 22 hours (range 18–26 h) in healthy adults, allowing once-daily dosing. Prolonged in renal impairment (up to 40 hours when CrCl <30 mL/min).
Norethindrone: 5-8 hours; Ethinyl estradiol: 7-15 hours; steady-state reached within 5-7 days
Renal excretion of unchanged drug accounts for approximately 70% of clearance; biliary/fecal elimination accounts for 30%. No active metabolites.
Renal (40% as metabolites), fecal (50% as metabolites), <1% unchanged
Category C
Category C
Combined Oral Contraceptive
Combined Oral Contraceptive